严重脓毒症与脓毒性休克患者预后分析

doi:10.6040/j.issn.1671-7554.0.2015.957

摘要/Abstract

摘要： 目的探讨严重脓毒症与脓毒性休克死亡危险因素,分层分析影响不同生存期患者预后的因素。方法回顾性分析2013年1月至2014年12月108例严重脓毒症与脓毒性休克患者临床资料,通过多因素Cox回归模型明确死亡的独立危险因素。结果总死亡率为53.7%,生存期<30 d,30 d~89 d,90 d~365 d患者死亡率分别为27.8%、24.4%与15.3%。急性生理与慢性健康评分(APACHE-Ⅱ评分)、查尔森合并症指数(CCI)与降钙素原变化率(△PCT)是影响死亡率的独立预后因素,HR(95%CI)分别为1.105(1.066~1.146)、1.390(1.210~1.596)与0.996(0.995~0.997)。分层分析,生存期<30 d者,预后因素为APACHE-Ⅱ评分(HR=1.104, 95%CI:1.052~1.158)、CCI(HR=1.462, 95%CI:1.204~1.775)、△PCT(HR=0.992, 95%CI:0.989~0.995)与ICU住院时间(HR=0.893, 95%CI:0.841~0.949);生存期30 d~89 d者,预后因素为APACHE-Ⅱ评分(HR=1.102, 95%CI:1.026~1.183)与△PCT(HR=0.996, 95%CI:0.994~0.998)。生存期90 d~365 d者,仅CCI(HR=1.689, 95%CI:1.065~2.679)影响预后。结论 APACHE-Ⅱ评分、CCI与△PCT为影响严重脓毒症与脓毒性休克患者死亡率的独立预后因素。但对于不同生存期的死亡患者,其预后因素稍有不同,需进一步开展多中心大样本的前瞻性队列研究证实。

关键词: 严重脓毒症, 脓毒性休克, 分层分析, 预后

Abstract: Objective To explore the prognostic factors for patients with severe sepsis and septic shock according to the survival periods. Methods Clinical data of 108 cases of severe sepsis and septic shock treated during Jan. 2013 and Dec. 2014 were retrospectively studied. The independent risk factors of death was analyzed with Cox porportional hazard models. Results The overall mortality was 53.7%, and the mortality at days 0-29, 30-89, and 90-365 was 27.8%, 24.4% and 15.3%, respectively. Factors significantly associated with mortality included APACHE-Ⅱscore(HR=1.105, 95%CI: 1.066-1.146), Charlson Comorbidities Index(CCI)(HR=1.390, 95%CI: 1.210-1.596)and procalcitonin changes(△PCT)(HR=0.996, 95%CI: 0.995-0.997). Results of stratified analysis according to different survival periods indicated that, APACHE-Ⅱscore(HR=1.104, 95%CI: 1.052-1.158), CCI(HR=1.462, 95%CI: 1.204-1.775), △PCT(HR=0.992, 95%CI: 0.989-0.995), and days of ICU-stay(HR=0.893, 95%CI: 0.841-0.949)were the prognostic factors for patients who survived for less than 30 days; risk factors associated with mortality included APACHE-Ⅱscore(HR=1.102, 95%CI: 1.026-1.183)and △PCT(HR=0.996, 95%CI: 0.994-0.998)for patients who survived for 30 d-89 d; for patients survived for 90 d-365 d, CCI(HR=1.689, 95%CI: 1.065-2.679)was the only prognostic factor. Conclusions APACHE-Ⅱscore, CCI and △PCT are the independent 山东大学学报 (医学版)54卷10期 -刘晓,等.严重脓毒症与脓毒性休克患者预后分析 \=-prognostic factors for patients with severe sepsis and septic shock, while there were slight differences among different survival periods. It is necessary to develop a multicenter large-scale prospective cohort study for further confirmation.

Key words: Stratified analysis, Severe sepsis, Septic shock, Prognosis

中图分类号:

R631

刘晓,刘志广,范志松,王媛,杨兴肖,孔洁羽,陈俊卓,刘俊霞. 严重脓毒症与脓毒性休克患者预后分析[J]. 山东大学学报（医学版）, 2016, 54(10): 80-84.

LIU Xiao, LIU Zhiguang, FAN Zhisong, WANG Yuan, YANG Xingxiao, KONG Jieyu, CHEN Junzhuo, LIU Junxia. Prognostic analysis of patients with severe sepsis and septic shock[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(10): 80-84.

参考文献

[1] Cawcutt KA, Peters SG. Severe sepsis and septic shock: clinical overview and update on management[J]. Mayo Clin Proc, 2014, 89(11): 1572-1578.
[2] Blanco J, Muriel-Bombín A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: A Spanish multicentrestudy[J]. Crit Care, 2008, 12(6): R158.
[3] Rodríquez F, Barrera L, De La Rosa G, et al. The epidemiology of sepsis in Colombia: a prospective multicenter cohort study in ten university hospitals[J]. Crit Care Med, 2011, 39(7): 1675-1682.
[4] 商娜,周荣斌. 脓毒症流行病学研究[J]. 中国急救医学, 2013, 33(1): 8-12. SHANG Na, ZHOU Rongbin. Research on the epidemiology of sepsis[J]. Chin J Crit Care Med, 2013, 33(1): 8-12.
[5] Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012[J]. Intensive Care Med, 2013, 39(2): 165-228.
[6] Baharoon S, Telmesani A, Tamim H, et al. Community-versus nosocomial-acquired severe sepsis and septic shock in patients admitted to a tertiary intensive care in Saudi Arabia, etiology and outcome[J]. J Infect Public Health, 2015, 8(5): 418-424.
[7] Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review[J]. Crit Care Med, 2010, 38(5): 1276-1283.
[8] 郑秀芹, 钟晓梅, 马建华, 等. 降钙素原结合APACHE-Ⅱ评分在老年重症感染患者中的诊断和预后意义[J]. 中国感染与化疗杂志, 2015, 15(1): 47-50. ZHENG Xiuqin, ZHONG Xiaomei, MA Jianhua, et al. Diagnostic and prognostic implication of procalcitonin combined with APACHE-Ⅱscore in elderly patients with severe infection[J]. Chin J Infect Chemother, 2015, 15(1): 47-50.
[9] 黄伟平, 江稳强, 胡北, 等. 降钙素原对全身炎症反应综合征患者病情预后的判断价值[J]. 中华危重病急救医学, 2012, 24(5): 294-297. HUANG Weiping, JIANG Wenqiang, HU Bei, et al. Significance of serum procalcitonin levels in the evaluation of severity and prognosis of patients with systemic inflammatory response syndrome[J]. Chin Crit Care Med, 2012, 24(5): 294-297.
[10] Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis, 1987, 40(5): 373-383.
[11] Yang Y, Yang KS, Hsann YM, et al. The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis[J]. J Crit Care, 2010, 25(3): 398-405.
[12] Storgaard M, Hallas J, Gahrn-Hansen B, et al. Short- and long-term mortality in patients with community-acquired severe sepsis and septic shock[J]. Scand J Infect Dis, 2013, 45(8): 577-583.
[13] Lemay AC, Anzueto A, Restrepo MI, et al. Predictors of long-term mortality after severe sepsis in the elderly[J]. Am J Med Sci, 2014, 347(4): 282-288.
[14] 马晓春. 应重视脓毒症的抗凝治疗[J]. 中华危重病急救医学, 2010, 22(9): 516-517.
[15] 中华医学会重症医学分会. 中国严重脓毒症/脓毒性休克治疗指南(2014)[J]. 中华危重病急救医学, 2015, 27(6): 401-426.
[16] 占志刚,李春盛. D-二聚体对急诊脓毒症患者预后价值的前瞻性研究[J]. 中华危重病急救医学,2012, 24(3): 135-138. ZHAN Zhigang, LI Chunsheng. Prognostic value of D-dimer in patients with sepsis in emergency department: a prospective study[J]. Chin Crit Care Med, 2012, 24(3): 135-138.
[17] “D-二聚体检测”急诊临床应用专家共识组. “D-二聚体检测”急诊临床应用专家共识[J]. 中华急诊医学杂志, 2013, 22(8): 827-836.

相关文章 15

[1]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[8]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[9]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[10]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[11]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[12]	杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[13]	刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[14]	宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[15]	刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed